MY153763A - Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof - Google Patents

Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof

Info

Publication number
MY153763A
MY153763A MYPI2010001434A MYPI20101434A MY153763A MY 153763 A MY153763 A MY 153763A MY PI2010001434 A MYPI2010001434 A MY PI2010001434A MY PI20101434 A MYPI20101434 A MY PI20101434A MY 153763 A MY153763 A MY 153763A
Authority
MY
Malaysia
Prior art keywords
preparation
therapeutic uses
quinazolinedione derivatives
quinazolinedione
derivatives
Prior art date
Application number
MYPI2010001434A
Other languages
English (en)
Inventor
Annie Clauss
Christophe Glaess
Gilbert Marciniak
Nicolas Muzet
Jean-François Nave
André Seyer
Bertrand Vivet
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MY153763A publication Critical patent/MY153763A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MYPI2010001434A 2007-10-03 2008-10-03 Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof MY153763A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0706931A FR2921926B1 (fr) 2007-10-03 2007-10-03 Derives de quinazolinedione,leur preparation et leurs applications therapeutiques.

Publications (1)

Publication Number Publication Date
MY153763A true MY153763A (en) 2015-03-13

Family

ID=39470387

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2010001434A MY153763A (en) 2007-10-03 2008-10-03 Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof

Country Status (40)

Country Link
US (1) US8242126B2 (enExample)
EP (1) EP2205593B1 (enExample)
JP (1) JP5411143B2 (enExample)
KR (1) KR20100082345A (enExample)
CN (1) CN101842368B (enExample)
AR (1) AR070655A1 (enExample)
AU (1) AU2008337382B2 (enExample)
BR (1) BRPI0818690A2 (enExample)
CA (1) CA2701150C (enExample)
CL (1) CL2008002946A1 (enExample)
CO (1) CO6270227A2 (enExample)
CR (1) CR11327A (enExample)
CY (1) CY1117461T1 (enExample)
DK (1) DK2205593T3 (enExample)
DO (1) DOP2010000089A (enExample)
EA (1) EA018766B1 (enExample)
EC (1) ECSP10010058A (enExample)
ES (1) ES2567567T3 (enExample)
FR (1) FR2921926B1 (enExample)
GT (1) GT201000069A (enExample)
HN (1) HN2010000572A (enExample)
HR (1) HRP20160359T1 (enExample)
HU (1) HUE028770T2 (enExample)
IL (1) IL204814A0 (enExample)
MA (1) MA31832B1 (enExample)
MX (1) MX2010003495A (enExample)
MY (1) MY153763A (enExample)
NI (1) NI201000039A (enExample)
NZ (1) NZ584430A (enExample)
PA (1) PA8797701A1 (enExample)
PE (1) PE20090960A1 (enExample)
PL (1) PL2205593T3 (enExample)
SI (1) SI2205593T1 (enExample)
SV (1) SV2010003514A (enExample)
TN (1) TN2010000130A1 (enExample)
TW (1) TWI421076B (enExample)
UA (1) UA99485C2 (enExample)
UY (1) UY31376A1 (enExample)
WO (1) WO2009077680A1 (enExample)
ZA (1) ZA201002307B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8107260B2 (en) * 2007-11-15 2012-01-31 Illinois Tool Works Inc. EMI shielding and environmental seal device
FR2943673B1 (fr) 2009-03-27 2013-03-29 Sanofi Aventis Applications therapeutiques de derives de quinazolinedione
FR2944282B1 (fr) * 2009-04-09 2013-05-03 Sanofi Aventis Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
FR2944206B1 (fr) * 2009-04-09 2012-12-28 Sanofi Aventis Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione
KR101116234B1 (ko) * 2009-10-29 2014-03-06 (주)퓨쳐켐 (3-플루오로-2-히드록시)프로필 작용기가 도입된 아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
AU2011261164A1 (en) * 2010-06-01 2012-12-13 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
WO2013161853A1 (ja) * 2012-04-24 2013-10-31 中外製薬株式会社 キナゾリンジオン誘導体
SG11201406871UA (en) 2012-04-24 2014-11-27 Chugai Pharmaceutical Co Ltd Benzamide derivative
WO2013184806A1 (en) 2012-06-05 2013-12-12 University Of Kansas Inhibitors of respiratory syncytial virus
WO2015003879A1 (en) * 2013-07-08 2015-01-15 Syngenta Participations Ag Microbiocidal heterobicylic derivatives
CA2927830A1 (en) 2013-10-23 2015-04-30 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
CZ2015601A3 (cs) * 2015-09-02 2017-03-15 Zentiva, K.S. Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty
CN107267455A (zh) * 2017-08-23 2017-10-20 安徽惠恩生物科技股份有限公司 一种嵌合抗原受体nk细胞的制备方法
GB201918416D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
CA3264513A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh USE OF SUBSTITUTED BENZOFURAN AND BENZOXAZOLE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERCISE INTOLERANCE
US12258345B1 (en) 2023-12-12 2025-03-25 King Faisal University Pyrrolo[3,2-c]isoquinoline-2,3-dione compounds as CK2 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
US5821366A (en) * 1995-05-19 1998-10-13 Chiroscience Limited Xanthines and their therapeutic use
JP2002308774A (ja) * 2001-04-12 2002-10-23 Nippon Zoki Pharmaceut Co Ltd Iv型ホスホジエステラーゼ選択的阻害剤
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
WO2006092692A1 (en) 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
KR20070107099A (ko) 2005-03-01 2007-11-06 화이자 리미티드 신경병증성 통증의 치료를 위한 pde7 억제제의 용도
US7846664B2 (en) 2005-12-07 2010-12-07 The Regents Of The University Of California Diagnosis and treatment of chronic lymphocytic leukemia (CLL)

Also Published As

Publication number Publication date
MA31832B1 (fr) 2010-11-01
FR2921926B1 (fr) 2009-12-04
CN101842368A (zh) 2010-09-22
BRPI0818690A2 (pt) 2015-04-14
EP2205593A1 (fr) 2010-07-14
ZA201002307B (en) 2011-06-29
CN101842368B (zh) 2014-03-12
CR11327A (es) 2010-09-13
NI201000039A (es) 2010-08-13
AU2008337382A1 (en) 2009-06-25
US20100298298A1 (en) 2010-11-25
TWI421076B (zh) 2014-01-01
WO2009077680A1 (fr) 2009-06-25
IL204814A0 (en) 2010-11-30
PA8797701A1 (es) 2009-05-15
KR20100082345A (ko) 2010-07-16
UA99485C2 (ru) 2012-08-27
JP5411143B2 (ja) 2014-02-12
ECSP10010058A (es) 2010-04-30
TW200922591A (en) 2009-06-01
HUE028770T2 (en) 2016-12-28
HRP20160359T1 (hr) 2016-05-06
SV2010003514A (es) 2011-01-31
JP2010540602A (ja) 2010-12-24
PE20090960A1 (es) 2009-08-10
UY31376A1 (es) 2009-05-29
CO6270227A2 (es) 2011-04-20
MX2010003495A (es) 2010-04-21
CA2701150A1 (fr) 2009-06-25
AU2008337382B2 (en) 2013-11-21
DK2205593T3 (en) 2016-04-18
CY1117461T1 (el) 2017-04-26
TN2010000130A1 (fr) 2011-09-26
EA201070424A1 (ru) 2011-04-29
EP2205593B1 (fr) 2016-01-13
PL2205593T3 (pl) 2016-09-30
ES2567567T3 (es) 2016-04-25
CL2008002946A1 (es) 2010-02-12
HN2010000572A (es) 2013-03-11
CA2701150C (fr) 2016-08-16
DOP2010000089A (es) 2010-05-15
SI2205593T1 (sl) 2016-05-31
EA018766B1 (ru) 2013-10-30
AR070655A1 (es) 2010-04-28
FR2921926A1 (fr) 2009-04-10
US8242126B2 (en) 2012-08-14
GT201000069A (es) 2012-03-26
NZ584430A (en) 2011-11-25

Similar Documents

Publication Publication Date Title
MY153763A (en) Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
WO2007061360A3 (en) Novel 3-bicyclocarbonylaminopyridine-2-carboxamides or 3-bicyclocarbonylaminopyrazine-2-carboxamides
TW200745067A (en) Novel compounds
MY151986A (en) Adamantyl diamide derivatives and uses of same
MX2009007713A (es) Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas.
TW200745114A (en) Novel compounds
MX2007005694A (es) Nuevos derivados de betulina, preparacion y uso de los mismos.
UA94833C2 (en) Substituted bicyclolactams
TW200745084A (en) Novel compounds
TW200800999A (en) Novel compounds
TW200801003A (en) Novel compounds
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
TW200942535A (en) Novel compounds as cannabinoid receptor ligands
DE602004024213D1 (en) Aminopropanolderivate
TW200738627A (en) Trialkylsilyl-indoles
MY146671A (en) Tetrahydronaphthaline derivatives, methods for the production and use thereof as anti-inflammatory agents
TN2012000105A1 (en) Spirolactam derivatives and uses of same
MX2009009490A (es) Profarmacos novedosos.
TW200716568A (en) 1H-quinazoline-2,4-diones
TW200639156A (en) New compounds
WO2008073863A3 (en) Preparation and utility of substituted allylamines